Form D · Biotechnology
Impact Proteomics, LLC
Pittsburgh, PA · CIK 0001804332
Offering snapshot reported Aug 14, 2024 · SEC filing
- Reported sold
- $50K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Aug 6, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2024 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Feb 21, 2020 | Initial | $200,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521472
Source: Form D, filed Aug 14, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Amber Lucas | Director, Executive |
| Jonathan Minden | Director, Executive, Promoter |
| Jeffrey Whitmore | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1406 Browning Road
Pittsburgh, PA, 15206
Pittsburgh, PA, 15206